Loading...
XNAS
QDEL
Market cap1.19bUSD
Jul 09, Last price  
17.44USD
1D
1.10%
1Q
25.92%
Jan 2017
-18.58%
Name

QuidelOrtho Corp

Chart & Performance

D1W1MN
XNAS:QDEL chart
P/E
P/S
0.44
EPS
Div Yield, %
Shrs. gr., 5y
9.24%
Rev. gr., 5y
10.44%
Revenues
2.73b
-1.89%
106,015,000118,065,000128,132,000164,282,000113,339,000158,603,000155,741,000175,410,000182,615,000196,129,000191,603,000277,743,000522,285,000534,890,0001,661,668,0001,698,600,0003,266,000,0002,997,800,0002,782,900,0002,730,200,000
Net income
-1.13b
L-44.84%
21,718,00013,631,00018,848,00032,883,000-11,271,0007,633,0004,993,0007,390,000-7,074,000-6,079,000-13,808,000-8,165,00074,183,00072,921,000810,287,000704,200,000548,700,000-10,100,000-2,052,000,000-1,131,800,000
CFO
105m
+26.75%
20,731,00027,342,00028,941,00072,843,000-10,293,00046,982,00019,633,00025,682,00035,686,00036,309,00011,815,00027,709,000136,345,000134,485,000629,763,000805,869,000885,300,000280,200,00083,000,000105,200,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

QuidelOrtho Corporation is dedicated to the creation and manufacturing of diagnostic testing technologies that address the full range of healthcare testing demands. The company operates through distinct business units: Laboratories, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics. The Laboratories segment provides instruments and assays for clinical chemistry, which measure specific chemical markers in bodily fluids to aid in health evaluation and patient management. It also offers immunoassay instruments and tests designed to detect proteins acting as antigens (indicating disease spread), antibodies (reflecting immune response), or markers of organ health and function. Furthermore, this unit develops testing solutions for monitoring disease progression across various therapeutic fields, along with specialized diagnostic tools. The Transfusion Medicine segment supplies immunohematology instruments and tests vital for blood typing, ensuring compatibility between patients and donors during transfusions, as well as donor screening instruments and tests for detecting infectious diseases in blood and plasma. The Point-of-Care business unit focuses on delivering rapid diagnostic tests suitable for diverse immediate care settings. Finally, the Molecular Diagnostics unit offers polymerase chain reaction (PCR) thermocyclers, alongside analyzers and amplification systems. QuidelOrtho distributes its products directly to end-users via its dedicated sales team and through a network of distributors. These offerings are employed professionally in a wide array of environments, including physician practices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening facilities, blood banks, and donor centers. The company's products are also available for individual, non-professional, and over-the-counter use. With operations spanning North America, Europe, the Middle East, Africa, China, and other global regions, QuidelOrtho Corporation was founded in 1979 and maintains its headquarters in San Diego, California.
IPO date
Feb 01, 1991
Employees
7,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT